Document Detail

T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats.
MedLine Citation:
PMID:  11430921     Owner:  NLM     Status:  MEDLINE    
Nitric oxide (NO) donors including organic nitrates dilate capacitance vessels. As inhibition of phosphodiesterase type 5 results in the accumulation of guanosine 3'5'-cyclic monophosphate (cGMP), specific phosphodiesterase type 5 inhibitors are expected to have a vasodilator property similar to that of NO donors. To test this hypothesis, we examined the effect of methyl2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel specific phosphodiesterase type 5 inhibitor, on mean arterial pressure and mean circulatory filling pressure (an index of venodilation) compared with that of nitroglycerin and diltiazem in mecamylamine- and noradrenaline-treated anesthetized rats. Intravenous infusion of T-1032 (0.1, 1, 10 microg/kg/min) dose-dependently decreased mean arterial pressure (-3.8+/-0.3%, -9.1+/-0.8%, -16.8+/-1.5% at doses of 0.1, 1 and 10 microg/kg/min, respectively) and mean circulatory filling pressure (-6.1+/-0.9%, -12.5+/-0.7%, -18.6+/-3.0% at doses of 0.1, 1 and 10 microg/kg/min, respectively). The mean circulatory filling pressure-mean arterial pressure relationship revealed that T-1032 had a selective action on the mean circulatory filling pressure compared with diltiazem (10, 100 microg/kg/min) and a similar or more selective effect than nitroglycerin (0.3, 3 and 30 microg/kg/min). In the next study, we calculated venous compliance and unstressed volume from the mean circulatory filling pressure-volume relationship. Intravenous infusion of T-1032 (3 microg/kg/min) increased venous compliance (3.35+/-0.40 in T-1032 vs. 2.31+/-0.15 ml/kg/mm Hg in vehicle, P<0.05) without changing the unstressed volume (37.2+/-2.80 in T-1032 vs. 42.6+/-2.37 ml/kg in vehicle, P>0.05). It was concluded that T-1032 increased venous capacitance by increasing venous compliance, and that this selective phosphodiesterase type 5 inhibitor appeared to have a different vasodilator action from that of an NO donor and a Ca(2+) channel antagonist in that it had a selective action on the mean circulatory filling pressure.
H Inoue; K Yano; T Ikeo; T Noto; K Kikkawa
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of pharmacology     Volume:  422     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-06-29     Completed Date:  2001-09-13     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  109-14     Citation Subset:  IM    
Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., 2-2-50, Kawagishi Toda, Saitama, 335-8505, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Diltiazem / pharmacology
Dose-Response Relationship, Drug
Ganglionic Blockers / pharmacology
Heart Rate / drug effects
Isoquinolines / pharmacology*
Mecamylamine / pharmacology
Nitroglycerin / pharmacology
Norepinephrine / pharmacology
Phosphodiesterase Inhibitors / pharmacology*
Pyridines / pharmacology*
Rats, Wistar
Vasoconstrictor Agents / pharmacology
Vasodilator Agents / pharmacology
Venous Pressure / drug effects*
Reg. No./Substance:
0/Ganglionic Blockers; 0/Isoquinolines; 0/Phosphodiesterase Inhibitors; 0/Pyridines; 0/T 1032; 0/Vasoconstrictor Agents; 0/Vasodilator Agents; 42399-41-7/Diltiazem; 51-41-2/Norepinephrine; 55-63-0/Nitroglycerin; 60-40-2/Mecamylamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increases in ornithine decarboxylase activity in the positive inotropism induced by androgens in iso...
Next Document:  Metoprolol attenuates postischemic depressed myocardial function in papillary muscles isolated from ...